NCT00505661 · STUDY IN CONTEXT

Letrozole in Patients With Ovarian Tumors

Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Using RECIST criteria, Objective Response evaluated every 2 months.

Analysis was per protocol, only 9 of 12 eligible patients were evaluable for response.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-malignant-peritoneal-neoplasm-vegzelma-2693c549
nct id: NCT00505661
trial label: Letrozole in Patients With Ovarian Tumors
applicability: unclear
applicability note: Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 1
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-malignant-peritoneal-neoplasm-vegzelma-2693c549
nct id
NCT00505661
outcome key
om-0000
source section id
NCT00505661-om-0000
source outcome index
0
endpoint
Objective Response Rate Following Treatment With Letrozole
endpoint definition
Using RECIST criteria, Objective Response evaluated every 2 months.
time origin
2 month intervals for first 2 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Analysis was per protocol, only 9 of 12 eligible patients were evaluable for response.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-malignant-peritoneal-neoplasm-vegzelma-2693c549
nct id
NCT00505661
outcome key
om-0000
arm key
OG000
arm label
Letrozole
regimen
2.5 mg by mouth (PO) daily
analyzed count
9
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00505661-om-0000#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-malignant-peritoneal-neoplasm-vegzelma-2693c549
nct id
NCT00505661
harm key
EG000
source section id
NCT00505661-ae
event group key
EG000
event group label
Letrozole
serious affected
0
serious at risk
16
other affected
4
other at risk
16
frequency threshold
5
collection period
4 years and 4 months
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice